Lupin Will Pay $150M To End Glumetza Antitrust Suit
By Lauren Berg · September 20, 2021, 10:10 PM EDT
Direct buyers of blood sugar medication Glumetza on Monday inked a $150 million deal in California federal court with Lupin Pharmaceuticals, which is accused of taking part in a scheme to...
To view the full article, register now.